Pharmaceutical

Eli Lilly And Co (NYSE:LLY) has capitalized on last week's impressive first-quarter earnings report.

Lilly surges after a Q1 beat and higher guidance, as Mounjaro and Zepbound fueled 56% revenue growth.

The S&P 500 has gained 5% this year, but there's the risk of a crash later in the year.

Dividend income arrives whether markets rally or sell off. For investors seeking recurring cash flow, high-yield equities remain the cleanest source outside a paycheck.

Eli Lilly ​said on ‌Wednesday it would ​commit ​an additional $4.5 billion ⁠investment across ​two ​of its three sites in ​Indiana, ​bringing the company's ‌total ⁠capital expansion commitments in the ​state ​since ⁠2020 to ​more ​than $21 ⁠billion.

Lilly's capital commitments to expand manufacturing in its home state now total $21 billion since 2020 Lilly Lebanon Advanced Therapies opens as company's first dedicated genetic medicine manufacturing facility LEBANON, Ind., May 6, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced an additional $4.5 billion investment across two of its three Lebanon sites—bringing the company

These stocks pay more than double the S&P 500 average and have modest valuations relative to the overall market.

South Korea Pharmaceutical Filtration Market Trends: Biopharma Growth, Sterile Processing & Forecast to 2033 vocal.media

Novo Nordisk stock rose as it raised its guidance on the back of the strong performance of its weight-loss pill.

DUBLIN, Ohio, May 5, 2026  /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved an increase to its quarterly dividend to $0.5158 per share, out of the Company's capital surplus. The dividend will be payable on July 15, 2026 to shareholders of record at the close of business on July 1, 2026.

Pfizer Inc. Chief Executive Officer Albert Bourla says President Donald Trump's nominee to lead the Centers for Disease Control and Prevention is a good choice. Bourla says Erica Schwartz is a “very credible scientist.

Just because a dividend stock has suffered a significant stumble doesn't mean the setback is permanent. It doesn't even mean its dividend is in jeopardy.

Novartis to close German manufacturing site, cutting 220 jobs Fierce Pharma

Pfizer Inc. (PFE) Q1 2026 Earnings Call Transcript

Pfizer beats Q1 estimates as new launches and acquired drugs lift sales, offsetting COVID declines, while the drugmaker reaffirms its 2026 outlook.

Pfizer (PFE) delivered a stronger-than-expected first quarter as demand for several older blockbusters helped cushion the continued drop in Covid-related revenu

Gaining An Edge In GLP-1 Production Bioprocess Online

Pfizer Inc (NYSE:PFE, XETRA:PFE) reported first-quarter 2026 revenue and adjusted profit above Wall Street expectations on Tuesday, driven by strong growth in its launched and acquired products, as the drugmaker reaffirmed its full-year financial outlook. The pharmaceutical giant posted revenue of $14.5 billion for the quarter ended March 31, up 5% from a year earlier and ahead of analyst estimate

This month's trio included a dividend aristocrat.

Pfizer reported Q1 revenues of $14.5bn, with adjusted EPS down 18% and a 6.54% dividend yield. PFE faces major patent expirations on key drugs like Eliquis and Vyndaqel, pressuring future revenues despite recent M&A and pipeline efforts. Recent acquisitions, including Seagen, have yet to deliver material commercial upside, while high debt limits further M&A flexibility, although the Metsera deal i

Eli Lilly (NYSE:LLY | LLY Price Prediction) received another bullish call from Wall Street.

Pfizer Inc  (NYSE:PFE) stock is down 1.1% to trade at $26.03 at last check.

Although the revenue and EPS for Pfizer (PFE) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Beyond analysts' top-and-bottom-line estimates for Becton Dickinson (BDX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2026.

Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Pfizer (PFE) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.71 per share. This compares to earnings of $0.92 per share a year ago.

Live Updates The analyst who called NVIDIA in 2010 just named his top 10 AI stocks This analyst's 2025 picks are up 106% on average. He just named his top 10 stocks to buy in 2026. Get them here FREE. Bitcoin Rallies $1,415 Higher - Here's Why. 58 minutes ago Live Bitcoin is up $1,415... Stock Market Live May 5, 2026: S&P 500 (SPY) Bounces on Pullback in Oil

Higher sales of cancer treatments helped fuel better-than-expected first-quarter sales and profit for the drugmaker.

Pfizer posted higher first-quarter revenue but lower profit that was weighed down partially by higher research and development spending.

The drugmaker has been leaning on recently acquired products to offset a looming patent cliff.

Investors are uncomfortable seeing losses, especially in stocks they rely on for steady income. Enterprise Products Partners (NYSE: EPD), Pfizer (NYSE: PFE) and UPS (NYSE: UPS) all fit that uneasy profile as the share prices have been battered, and the yields are high enough to make some investors wonder whether the market is flashing a warning.

By integrating the BD Pyxis™ Pro and BD Alaris™ platforms, Wellstar Health System is giving clinicians clearer insight, greater accuracy and simple automation, so they can focus on delivering safer, more consistent care to every patient FRANKLIN LAKES, N.J. and MARIETTA, Ga.

In LUCENT-3, more than 60% of patients who achieved disease clearance at one year maintained it after four years of continuous Omvoh treatment Disease clearance is a high clinical bar in UC requiring simultaneous symptomatic, endoscopic and histologic remission INDIANAPOLIS, May 5, 2026 /PRNewswire/ -- New long-term data from Eli Lilly and Company (NYSE: LLY) show patients with moderately to sever

Push for homegrown pharma factories gains urgency in war Arabian Gulf Business Insight | AGBI

ICU Medical's new high-volume pump has more connected features, which we believe will drive retention rates and incremental revenue. SiteOne Landscape Supply controls 18% of this $26 billion industry and has been growing revenue at a low double-digit compound annual growth rate over the past several years. Madison Small Cap Fund liquidated its position in Globus Medical after a multi-year period b

Eli Lilly (NYSE:LLY | LLY Price Prediction) just delivered one of the strongest first quarters in big pharma history, but shares have pulled back sharply from their February peak.

AbbVie ABBV stock has risen around 5% since it announced robust first-quarter 2026 results on April 29. It beat estimates for both earnings and sales and the guidance for 2026 revenues and earnings was also raised.

BD rides on Medical and Interventional product momentum, but China dynamics and research funding could weigh on second-quarter fiscal 2026 results.

Global drugmakers rush to boost US presence as tariff threat looms Reuters

Cardinal (CAH) is well positioned to outperform the market, as it exhibits above-average growth in financials.

In Q1 2026, Polen Focus Growth Portfolio returned -17.27% (net of fees) compared to -9.78% for the Index. Starbucks was the top performing absolute and relative contributor in Q1 amid positive signs that CEO Brian Nicol's multi-year turnaround strategy is beginning to bear fruit. In Q1 2026, we initiated new positions in Lam Research, Meta and Rollins, while we sold our holdings in Abbott Laborato

INDIANAPOLIS, May 4, 2026 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2026 of $1.73 per share on outstanding common stock. The dividend is payable on June 10, 2026, to shareholders of record at the close of business on May 15, 2026.

Cardinal (CAH) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

The Food and Drug Administration has recorded two ‘serious' cases in patients taking Eli Lilly's weight-loss pill.

I keep buying Eli Lilly (NYSE:LLY | LLY Price Prediction), and the latest quarter just made it harder to stop.

AstraZeneca opens $360m drug manufacturing facility in Dublin as Ireland bets on pharma resilience Euractiv

Mounjaro and Zepbound are driving Eli Lilly's earnings sharply higher. Foundayo looks like another top-seller.

Abbott Laboratories (ABT 1.47%) is offering income investors a rare setup: a yield is approaching 3% while the business continues to grow. The stock isn't a screaming bargain, and rising costs matter, but its record as a Dividend King (increasing its dividends for 50+ consecutive years) makes this healthcare giant worth a closer look.

Pharmaceutical Manufacturing: AstraZeneca's UK Expansion Manufacturing Digital